Marked iron overload related to ribavirin and iron sulfate treatment in a patient with active viral C cirrhosis.
Increased ferritin levels are common in the course of chronic hepatitis C, regardless of antiviral therapy. Usually, this increase in ferritin levels has minimal clinical and biological impact, and drops after therapy discontinuation. We report here on a dramatic increase in ferritin levels in a cirrhotic patient with hepatitis C treated by ribavirin monotherapy and oral iron sulphate, and discuss the possible mechanisms of this deleterious effect.
Jouannaud
Vincent
V
Service d'Hépato-Gastroentérologie et de Nutrition, Hôpital Laënnec, Boulevard Laënnec, Creil, France.
Cadranel
Jean-François
JF
Dumouchel
Patrice
P
Cazier
Alain
A
Capron
Dominique
D
Rochette
Jacques
J
Barbare
Jean-Claude
JC
D000998:Antiviral Agents / Q000009:adverse effects*; D004359:Drug Therapy, Combination; D005260:Female; D005293:Ferritins / Q000097:blood; D005296:Ferrous Compounds / Q000009:adverse effects*; D019698:Hepatitis C, Chronic / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D019190:Iron Overload / Q000139:chemically induced*; D008875:Middle Aged; D012254:Ribavirin / Q000009:adverse effects*
D000998:Antiviral Agents; D005296:Ferrous Compounds; C020748:ferrous sulfate; D012254:Ribavirin; D005293:Ferritins